There are 2789 resources available
571P - Real-life monocentric, retrospective study on efficacy and tolerability of lenvatinib (Len) in patients (pts) with advanced radioactive iodine–refractory differentiated thyroid cancer (rDTC)
Presenter: Stefania Zovato
Session: ePoster Display
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Presenter: Javier Pozas
Session: ePoster Display
535P - Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Marcia S. Brose
Session: ePoster Display
536P - Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
Presenter: Theodore W. Laetsch
Session: ePoster Display
537P - Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
Presenter: Stefanie Krens
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display